Unprecedented survival results for B-MS Yervoy and Roche's vemurafenib in melanoma discussed at ASCO
There was exciting news presented at this year’s American Society of Clinical Oncology meeting for patients with metastatic melanoma from US drug major Bristol-Myers Squibb (NYSE: BMY) and Switzerland’s Roche (ROG: SIX), which presented new data on Yervoy (ipilimumab) and vemurafenib, two competitive drugs for the treatment of this lethal condition which the two companies have also agreed to test as a combination therapy (The Pharma Letter June 3).
"This is really an unprecedented time of celebration for our patients," said Dr. Lynn Schuchter, of the University of Pennsylvania's Abramson Cancer Center, quoted by The Associated Press. The new drugs are not by themselves cures, but "the future is going to be to build upon the success" by testing combinations of these newer drugs, she noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze